These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 18980195)

  • 1. Cocultures of osteoblasts and osteoclasts are influenced by local application of zoledronic acid incorporated in a poly(D,L-lactide) implant coating.
    Greiner S; Kadow-Romacker A; Schmidmaier G; Wildemann B
    J Biomed Mater Res A; 2009 Oct; 91(1):288-95. PubMed ID: 18980195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of zoledronic acid incorporated in a poly(D,L-lactide) implant coating on osteoblasts in vitro.
    Greiner S; Kadow-Romacker A; Lübberstedt M; Schmidmaier G; Wildemann B
    J Biomed Mater Res A; 2007 Mar; 80(4):769-75. PubMed ID: 17041912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of β-tricalcium phosphate coated with zoledronic acid on human osteoblasts and human osteoclasts in vitro.
    Kadow-Romacker A; Greiner S; Schmidmaier G; Wildemann B
    J Biomater Appl; 2013 Jan; 27(5):577-85. PubMed ID: 21862509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonates incorporated in a poly(D,L-lactide) implant coating inhibit osteoclast like cells in vitro.
    Greiner S; Kadow-Romacker A; Wildemann B; Schwabe P; Schmidmaier G
    J Biomed Mater Res A; 2007 Dec; 83(4):1184-1191. PubMed ID: 17595027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age of donor alters the effect of cyclic hydrostatic pressure on production by human macrophages and osteoblasts of sRANKL, OPG and RANK.
    Evans CE; Mylchreest S; Andrew JG
    BMC Musculoskelet Disord; 2006 Mar; 7():21. PubMed ID: 16519799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local application of zoledronic acid incorporated in a poly(D,L-lactide)-coated implant accelerates fracture healing in rats.
    Greiner SH; Wildemann B; Back DA; Alidoust M; Schwabe P; Haas NP; Schmidmaier G
    Acta Orthop; 2008 Oct; 79(5):717-25. PubMed ID: 18839381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts.
    Viereck V; Emons G; Lauck V; Frosch KH; Blaschke S; Gründker C; Hofbauer LC
    Biochem Biophys Res Commun; 2002 Mar; 291(3):680-6. PubMed ID: 11855844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of local zoledronate on implant osseointegration in a rat model.
    Back DA; Pauly S; Rommel L; Haas NP; Schmidmaier G; Wildemann B; Greiner SH
    BMC Musculoskelet Disord; 2012 Mar; 13():42. PubMed ID: 22439827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in the fusion and resorption activity of human osteoclasts after stimulation with different growth factors released from a polylactide carrier.
    Wildemann B; Kadow-Romacker A; Lübberstedt M; Raschke M; Haas NP; Schmidmaier G
    Calcif Tissue Int; 2005 Jan; 76(1):50-5. PubMed ID: 15477999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical evaluation of zoledronate using an in vitro mimetic cellular model for breast cancer metastatic bone disease.
    Dedes PG; Kanakis I; Gialeli Ch; Theocharis AD; Tsegenidis T; Kletsas D; Tzanakakis GN; Karamanos NK
    Biochim Biophys Acta; 2013 Jun; 1830(6):3625-34. PubMed ID: 23395844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption.
    Michael H; Härkönen PL; Väänänen HK; Hentunen TA
    J Bone Miner Res; 2005 Dec; 20(12):2224-32. PubMed ID: 16294275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
    Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
    J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
    Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y
    Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silicate modulates the cross-talk between osteoblasts (SaOS-2) and osteoclasts (RAW 264.7 cells): inhibition of osteoclast growth and differentiation.
    Schröder HC; Wang XH; Wiens M; Diehl-Seifert B; Kropf K; Schloßmacher U; Müller WE
    J Cell Biochem; 2012 Oct; 113(10):3197-206. PubMed ID: 22615001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. OPG-Fc but Not Zoledronic Acid Discontinuation Reverses Osteonecrosis of the Jaws (ONJ) in Mice.
    de Molon RS; Shimamoto H; Bezouglaia O; Pirih FQ; Dry SM; Kostenuik P; Boyce RW; Dwyer D; Aghaloo TL; Tetradis S
    J Bone Miner Res; 2015 Sep; 30(9):1627-40. PubMed ID: 25727550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlled delivery of zoledronate improved bone formation locally in vivo.
    Gou W; Wang X; Peng J; Lu Q; Wang Y; Wang A; Guo Q; Gao X; Xu W; Lu S
    PLoS One; 2014; 9(3):e91317. PubMed ID: 24618585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the effects of genistein and zoledronic acid on the bone loss in OPG-deficient mice.
    Liu J; Xu K; Wen G; Guo H; Li S; Wu X; Dai R; Sheng Z; Liao E
    Bone; 2008 May; 42(5):950-9. PubMed ID: 18337202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of bone resorption and growth of breast cancer in the bone microenvironment.
    Buijs JT; Que I; Löwik CW; Papapoulos SE; van der Pluijm G
    Bone; 2009 Feb; 44(2):380-6. PubMed ID: 19041433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteoclasts but not osteoblasts are affected by a calcified surface treated with zoledronic acid in vitro.
    Schindeler A; Little DG
    Biochem Biophys Res Commun; 2005 Dec; 338(2):710-6. PubMed ID: 16243296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mesoporous silica nanoparticles/hydroxyapatite composite coated implants to locally inhibit osteoclastic activity.
    Zhu M; Zhu Y; Ni B; Xie N; Lu X; Shi J; Zeng Y; Guo X
    ACS Appl Mater Interfaces; 2014 Apr; 6(8):5456-66. PubMed ID: 24666121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.